FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to methods for preparing pharmaceutical compounds for injections. To prevent agglutination, the prepared pharmaceutical compound shall have sufficient ionic strength. To prevent haemolysis or cell compression, the prepared injection pharmaceutical compound shall be roughly isotonic in relation to plasma. The method involves application of saline solutions of the concentration approximately 25 mM to 150 mM for transfer lyophilizates into the solution (or the other pharmaceutical compounds which are not liquids) or for solution dilutions on the basis of pharmaceutical compounds.
EFFECT: prepared compounds if introduced do not cause hemagglutination, haemolysis or cell compression.
26 cl, 4 ex, 9 tbl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| LIQUID PROTEIN FORMULATIONS CONTAINING IONIC LIQUIDS | 2014 |
|
RU2675824C2 |
| METHOD FOR PURIFYING VITAMIN K DEPENDENT PROTEINS SUCH AS COAGULATION FACTOR IX | 2011 |
|
RU2590726C2 |
| METHOD OF PURIFYING VITAMIN K-DEPENDENT PROTEINS, SUCH AS COAGULATION FACTOR VII | 2011 |
|
RU2731720C2 |
| STABILISED IX FACTOR AND TREGALOSE- CONTAINING COMPOSITIONS | 2008 |
|
RU2481823C2 |
| VACCINE COMPOSITIONS AGAINST HUMAN PAPILLOMA VIRUS (HPV), CONTAINING ALUMINIUM ADJUVANT, AND METHODS OF PRODUCTION THEREOF | 2012 |
|
RU2610174C2 |
| LIQUID FORMULATIONS OF PROTEINS CONTAINING VISCOSITY-LOWERING AGENTS | 2022 |
|
RU2833959C2 |
| HUMAN PARATHYROID HORMONE (PTH) FORMULATIONS AND METHODS FOR PREPARING THEREOF | 2020 |
|
RU2820316C1 |
| LIQUID PROTEIN COMPOSITIONS CONTAINING VISCOSITY-REDUCING AGENTS | 2014 |
|
RU2782765C2 |
| LIQUID COMPOSITIONS OF PROTEINS CONTAINING AGENTS FOR VISCOSITY REDUCTION | 2014 |
|
RU2710542C2 |
| INFUSION SOLUTION | 2019 |
|
RU2708389C1 |
